Foghorn Therapeutics Inc. (FHTX)
| Market Cap | 303.48M |
| Revenue (ttm) | 30.91M |
| Net Income (ttm) | -74.28M |
| Shares Out | 58.70M |
| EPS (ttm) | -1.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 129,034 |
| Open | 5.24 |
| Previous Close | 5.21 |
| Day's Range | 5.07 - 5.25 |
| 52-Week Range | 3.27 - 6.95 |
| Beta | 3.11 |
| Analysts | Strong Buy |
| Price Target | 11.50 (+122.44%) |
| Earnings Date | May 13, 2026 |
About FHTX
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leuk... [Read more]
Financial Performance
In 2025, Foghorn Therapeutics's revenue was $30.91 million, an increase of 36.75% compared to the previous year's $22.60 million. Losses were -$74.28 million, -14.24% less than in 2024.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for FHTX stock is "Strong Buy." The 12-month stock price target is $11.5, which is an increase of 122.44% from the latest price.
News
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models
Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
New preclinical data for FHD-909 (LY4050784) reinforcing the potential for expansion opportunities in combination with an anti-PD-1 antibody in SMARCA4 (BRG1)-mutant lung cancer
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
FHD-909 (LY4050784) Phase 1 dose-escalation advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC)
Foghorn Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The company highlighted progress in its oncology-focused pipeline, including a key partnership with Eli Lilly on the SMARCA2 program, which is advancing through dose escalation with a dose expansion decision expected mid-year. Selective CBP, EP300, and ARID1B degrader programs are moving toward IND-enabling studies, and recent financing extends the operational runway.
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial Officer
WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The discussion highlighted the scientific rationale for targeting chromatin regulatory complexes in cancer, detailed progress on SMARCA2 (in partnership with Lilly) and wholly owned CBP/EP300 programs, and outlined clinical and preclinical advances. Key updates and expansion decisions are expected later this year.
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit
WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
WATERTOWN, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
Recently raised $50 million with BVF Partners, Deerfield Management, founding investor Flagship Pioneering and a leading biotech mutual fund in a transaction that will close January 13 th , 2026
Foghorn Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
The company is advancing a precision oncology pipeline focused on chromatin regulation, with its lead 909 program in partnership with Lilly targeting SMARCA2 in non-small cell lung cancer. Strong enrollment and promising preclinical data support a potential move to first-line settings and pipeline expansion in 2024.
Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics Transcript: Jefferies London Healthcare Conference 2025
A major partnership with Eli Lilly drives the SMARCA2 program, with a key dose expansion decision expected in H1 2026. Proprietary assets targeting chromatin regulators are advancing toward IND, and the company is well-funded into early 2028.
Foghorn Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Chromatin regulation is a key focus, with selective targeting of SMARCA2 in cancers with SMARCA4 loss showing strong preclinical and early clinical promise. The pipeline includes advanced CBP and EP300 programs and a novel ARID1B degrader, all aiming for improved selectivity and tolerability.
Foghorn Therapeutics Provides Third Quarter 2025 Financial and Corporate Update
Ongoing FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1)-mutated cancer remains on track with non-small cell lung cancer (NSCLC) as the primary target population Selective CBP degr...
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by...
Foghorn Therapeutics Transcript: 8th Annual Targeted Protein Degradation & Induced Proximity Summit
The conference detailed significant progress in developing selective protein degraders for cancer, including robust ARID1B, CBP, and EP300 programs, with multiple candidates advancing toward IND-enabling studies in 2026. Selective degradation strategies offer efficacy and safety advantages, and industry feedback on ARID1B was highly positive.
Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs
- Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors
Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit
Foghorn to host a virtual investor event on updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs on Thursday October 30, 2025, at 12 p.m. EDT Foghorn to host a virtual...
IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies
RESEARCH TRIANGLE PARK, N.C. and CAMBRIDGE, Mass.
Foghorn Therapeutics Provides Second Quarter 2025 Financial and Corporate Update
FHD-909 (LY4050784) Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population, is enrolling well and remains on track
Foghorn Therapeutics Transcript: Jefferies Global Healthcare Conference 2025
The discussion highlighted advances in targeting the chromatin regulatory system, with a focus on selective inhibition and degradation of challenging proteins like SMARCA2, CBP, and EP300. Key clinical trials are underway, with important data and potential new targets expected over the next 12–18 months.
Foghorn Therapeutics to Participate in Four Upcoming Investor Conferences
CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by ...
Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update
FHD-909 (LY4050784) advancing in Phase 1 dose escalation trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population Data presented at AACR show s...
Foghorn Therapeutics to Participate in the Citizens Life Sciences Conference
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by ...